Intraoperative ShiveringNCT06091657
Comparison of Ketamine Plus Dexamethasone Versus Ketamine Alone for Prevention of Severe Shivering After Spinal Anesthesia in Cesarean Section
A study testing Ketamine Hydrochloride in people with Intraoperative Shivering and Ketamine With Shivering, run by Kasr El Aini Hospital at 1 site in Egypt.
Trial summary
Shivering is one of the most distressing events of the birth experience for patients. Shivering that occurs with spinal anesthesia is a frequent event, with a reported incidence of up to 50-65%. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Intraoperative Shivering, Ketamine With Shivering, Dexamethasone for Shivering
- What is being tested?
- Ketamine Hydrochloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2024to 30 Jul 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- 1. Inclusion criteria
- pregnant females
- aged 18 to 45 years
- ASA physical status II
- elective Cesarean sections under spinal anesthesia
- 2. Exclusion criteria
Show all 13Show fewer
- Contraindications for spinal anesthesia
- Emergency cesarean sections
- Patient with initial body temperature \>38°c or \<36°c
- Allergy to any of the drugs used in the study
- Pre Existing neurological diseases (particularly those that wax and wane, e.g.multiple sclerosis)
- Thrombocytopenia and coagulation disorders.
- Severe stenotic heart disease.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Shivering is one of the most distressing events of the birth experience for patients. Shivering that occurs with spinal anesthesia is a frequent event, with a reported incidence of up to 50-65%. (1) This may be normal thermoregulatory shivering in response to core hypothermia or may result from the release of cytokines by the surgical procedure. (2-4) shivering is graded with a scale described by Bedside Shivering Assessment Score (BSAS). (3, 4) Most of the literature recommends a variety of non-pharmacological and pharmacological options for the prevention and treatment of shivering after spinal anesthesia. Pethidine, tramadol, clonidine, dexmedetomidine, biogenic amines (serotonin 5-HT3 receptor antagonist), low-dose ketamine, dexamethasone, and magnesium sulfate were used as pharmacological agents. (5) Intravenous (IV) ketamine 0.25 mg/kg was approved as effective in the prevention and treatment of shivering after regional anesthesia and can be used in patients undergoing cesarean sections without adverse effects on the baby. (5) Ketamine is a competitive N-methyl-D-aspartate receptor antagonist, and it is believed that its anti-shivering action is due to non-shivering thermogenesis, either by effect on the hypothalamus or by the β-adrenergic effect of norepinephrine. (6) In spite of the approved effectiveness of ketamine in this issue, moderate to severe shivering (grade ≥ 2) still occurs with an incidence that cannot be ignored. (7-9) Dexamethasone was also approved as an alternative pharmacological agent for the prevention and treatment of mild and moderate shivering. (10) Dexamethasone prevents shivering by regulating immune response and decreasing the temperature gradient between skin and body core via its anti-inflammatory action and inhibition of the release of vasoconstrictors and pyrogenic cytokines. We hypothesize that addition of dexamethasone (0.1 mg\kg) to low dose ketamine (0.25 mg\kg) will be more effective in prevention of severe shivering after spinal anesthesia with cesarean section with minimal sedation of the mother and negligible effect on the baby. This can be applicable in resource-limited settings.
Read the detailed description
- Preoperatively, a trained anesthetist will assess the patients regarding the age, height; weight. Medical history, medications, laboratory investigation, as well as the patient's airway. Fasting hours will be reviewed(8 hours) In the operating room; temperature will be maintained at 24 °c -26° c by adjusting the temperature setting of the air conditioner.
- Routine monitors (electrocardiogram, pulse oximetry, and non-invasive blood pressure monitor) will be applied \& axillary temperature will be recorded; then intravenous access (18-G cannula) will be inserted and pre-medication ranitidine 40 mg will be administered.
- Baseline vitalsigns will be recorded in the supine position. Ringer lactate infusion (which is kept at room temperature 24°c -26°c) will be started at a rate of 10 ml/kg for the first 30 minutes then reduced to 6 ml/kg till the end of the surgery.
- drug preparation:
An independent research assistant will be responsible for opening the envelopes and preparing the study drug with no further involvement in the study. The attending anesthetist and data collector will be blinded to the study group.
Group K (ketamine):
syringe (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.
syringe (2): saline syringe 10 ml saline in 10 ml syringe. (for double blinded technique). we will give 0.1ml/kg of the syringe.
Group KD (ketamine plus dexamethasone):
Syringes (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.
Syringe (2): dexamethasone syringe, 10 mg dexamethasone will be diluted with 10 ml saline in 10 ml syringe, concentration will be 1mg/ml. the dose will be 0.1 mg/kg, so we will give 0.1ml/kg of the syringe.
The drugs will be given to the patient by direct intravenous injection through the cannula and flushing with normal saline after administration of the drugs.
Recording of vital signs (arterial blood pressure, heart rate, oxygen saturation axillary temperature) then shifting the patient to the sitting position with a nurse in front of her for administration of subarachnoid block In the sitting posture, a 25G Quincke's spinal needle is used to puncture the L3-L4 interspace under sterile conditions and via the midline route.
After the CSF free flow, 12-15 mg hyperbaric bupivacaine will be givenIntrathecal (according to the patient's height) and the patient will be placed in a supine posture with 15 degrees tilt to left side with a wedge under right iliac bone. Patients will be given 3 liters of oxygen per minute through the nasal cannula.
After spinal anesthesia , arterial blood pressure, heart rate and oxygen saturation will all be recorded immediately after shifting the patient to supine position.
Hypotension is defined as a drop in mean arterial blood pressure (more than 20% below baseline) following spinal injection, and it is treated by increasing intravenous fluid administration and administering 2.5-5 milligrams increments of ephedrine I.V. (every 3-5 minutes) until the hypotension is resolved.
After the sensory block at the level of T4-T6 is confirmed by the lack of sensitivity to cold, surgery will begin. The heart rate, oxygen saturation,are continuously monitored and the blood pressure readings will be taken every 10 minutes till the end of the surgery.
During surgery, a shivering score will be recorded at 15 min intervals and axillary temperature will be recorded after 30 minutes then at the end of the surgery.
Rescue dose of pethidine (25 mg) could be given intravenously if the participant developed grade 3 or grade 4 shivering
- Apgar score of the baby will be recorded as a secondary outcome.
- The level of sedation of the mother using The University of Michigan Sedation Scale (UMSS) will be recorded.
Post operative monitoring:
The participants will be monitored post-operatively for 60 minutes regarding their hemodynamics and shivering score.
Any complications in the Intra operative and post-operative period will be recorded.
- Measurement tools
- Demographic data as age, sex, BMI, medications, drug allergy and any other comorbidity.
- Heart rate, SpO2, and non-invasive arterial blood pressure will be monitored and recorded before spinal anesthesia and every 10 minutes after spinal anesthesia till the end of the procedure.
- Length of operation and the number of shivering episodes scored ≥2 will be recorded.
- Temperature: axillary temperature will be measured before, immediately and 30 minutes after induction of spinal anesthesia, and at the end of surgery.
- Hemodynamics, temperature, shivering episodes will be recorded for 60 minutes postoperatively.
- Bedside Shivering Assessment Scale shivering score will be recorded at 15 min intervals till the end of the procedure and for 60 minutes in post anesthesia care unit
- Grade 0 if there is no shivering
- Grade 1 if there is no muscle contraction but mild fasciculation of face or neck or peripheral vasoconstriction but no visible shivering
- Grade 2 if there is a visible muscular activity in only one muscle group
- Grade 3 if the muscular activity is in more than one muscle group but not generalized
- Grade 4 if gross muscular activity involving the entire body.
- The level of sedation of the mother will be recorded using The University of Michigan Sedation Scale (UMSS).
Table 1: The University of Michigan Sedation Scale (UMSS)(Liu et al., 2018) Value Patient state 0 • Awake and alert.
- • Minimally sedated: tired/ sleepy, appropriate response to verbal conversation, and/or sound.
- • Moderately sedated: somnolent/ sleeping, easily aroused with light tactile stimulation or a simple verbal command.
- • Deeply sedated: deep sleep, roused only with significant physical stimulation.
- • Unarousable.
- .Table 2: Apgar score (Simon et al., 2017) Score 0 points 1 point 2 points Appearance (Skin color) Cyanotic / pale all over Peripheral cyanosis only. Pink Pulse (Heart rate) 0 <100 100-140 Grimace (Reflex irritability) No response to stimulation Grimace or weak cry when stimulated Cry when stimulated Activity (Tone) Floppy Some flexions Well flexed and resisting extension Respiration Apneic Slow, irregular Strong cry
VI. Study outcomes:
- Primary outcome:
- the incidence of shivering attacks intraoperative. ( using Bedside Shivering Assessment Scale)
- Secondary outcomes:
- Apgar score at 1 and 5 minutes, Apgar is a quick test performed on a baby at 1 and 5 minutes after birth. The 1-minute score determines how well the baby tolerated the birthing process. The 5-minute score tells the health care provider how well the baby is doing outside the mother's womb. It also helps measure how well the baby responds if resuscitation is needed right after birth.
- Intraoperative hemodynamics assessment Immediately after injection of the medications and every 10 minutes till the end of the procedure including: heart rate, arterial blood pressure and number of hypotensive episodes
- Sedation of the mother immediately after injection of drug and after 30 minutes using The University of Michigan Sedation Scale (UMSS)
- Conditions
- Intraoperative Shivering, Ketamine With Shivering, Dexamethasone for Shivering, Severe Shivering
- Being tested
- Ketamine Hydrochloride
- Keywords
- shivering, ketamine, dexamethasone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ketamine HydrochlorideDrug
Also called dexamethasone
intravenous injection
| Study group | Role | What they receive |
|---|---|---|
| ketamine group | Active comparator | Group K (ketamine):
syringe (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.
syringe (2): saline syringe 10 ml saline in 10 ml syringe. (for double blinded technique). we will give 0.1ml/kg of the syringe. Receives: Drug: Ketamine Hydrochloride |
| ketamine dexamethasone group | Active comparator | Group KD (ketamine plus dexamethasone):
Syringes (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.
Syringe (2): dexamethasone syringe, 10 mg dexamethasone will be diluted with 10 ml saline in 10 ml syringe, concentration will be 1mg/ml. the dose will be 0.1 mg/kg, so we will give 0.1ml/kg of the syringe. Receives: Drug: Ketamine Hydrochloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
number of shivering episodes
● the number of shivering episodes scored ≥3 will be recorded.
Measured: the whole procedure and for 60 minutes postoperative
Secondary outcomes (3)
sedation score of the mother
Measured: 120 minutes
APGAR score of the baby
Measured: 5 minutes
hemodynamics
Measured: 120 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2023
- Study start1 Jan 2024
- Primary completion15 Jul 2024
- Study completion30 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intraoperative ShiveringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 110 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amany Ahmed Eissa, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06091657
- Sponsor's protocol ID
- MS-525-2023
- Status last verified
- Jan 2025
- First submitted
- 16 Oct 2023
- Last updated
- 17 Jan 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Ketamine Plus Dexamethasone Versus Ketamine Alone for Prevention of Severe Shivering After Spinal Anesthesia in Cesarean Section
- ClinicalTrials.gov ID
- NCT06091657
- Acronym / sponsor ID
- MS-525-2023
- Conditions
- Intraoperative Shivering, Ketamine With Shivering, Dexamethasone for Shivering, Severe Shivering
- Keywords
- shivering, ketamine, dexamethasone
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 110 participants (actual)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 15 Jul 2024 (actual)
- Study completion
- 30 Jul 2024 (actual)
- First posted
- 19 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Shivering is one of the most distressing events of the birth experience for patients. Shivering that occurs with spinal anesthesia is a frequent event, with a reported incidence of up to 50-65%. (1) This may be normal thermoregulatory shivering in response to core hypothermia or may result from the release of cytokines by the surgical procedure. (2-4) shivering is graded with a scale described by Bedside Shivering Assessment Score (BSAS). (3, 4) Most of the literature recommends a variety of non-pharmacological and pharmacological options for the prevention and treatment of shivering after spinal anesthesia. Pethidine, tramadol, clonidine, dexmedetomidine, biogenic amines (serotonin 5-HT3 receptor antagonist), low-dose ketamine, dexamethasone, and magnesium sulfate were used as pharmacological agents. (5) Intravenous (IV) ketamine 0.25 mg/kg was approved as effective in the prevention and treatment of shivering after regional anesthesia and can be used in patients undergoing cesarean sections without adverse effects on the baby. (5) Ketamine is a competitive N-methyl-D-aspartate receptor antagonist, and it is believed that its anti-shivering action is due to non-shivering thermogenesis, either by effect on the hypothalamus or by the β-adrenergic effect of norepinephrine. (6) In spite of the approved effectiveness of ketamine in this issue, moderate to severe shivering (grade ≥ 2) still occurs with an incidence that cannot be ignored. (7-9) Dexamethasone was also approved as an alternative pharmacological agent for the prevention and treatment of mild and moderate shivering. (10) Dexamethasone prevents shivering by regulating immune response and decreasing the temperature gradient between skin and body core via its anti-inflammatory action and inhibition of the release of vasoconstrictors and pyrogenic cytokines. We hypothesize that addition of dexamethasone (0.1 mg\kg) to low dose ketamine (0.25 mg\kg) will be more effective in prevention of severe shivering after spinal anesthesia with cesarean section with minimal sedation of the mother and negligible effect on the baby. This can be applicable in resource-limited settings.
Detailed description
- Preoperatively, a trained anesthetist will assess the patients regarding the age, height; weight. Medical history, medications, laboratory investigation, as well as the patient's airway. Fasting hours will be reviewed(8 hours) In the operating room; temperature will be maintained at 24 °c -26° c by adjusting the temperature setting of the air conditioner.
- Routine monitors (electrocardiogram, pulse oximetry, and non-invasive blood pressure monitor) will be applied \& axillary temperature will be recorded; then intravenous access (18-G cannula) will be inserted and pre-medication ranitidine 40 mg will be administered.
- Baseline vitalsigns will be recorded in the supine position. Ringer lactate infusion (which is kept at room temperature 24°c -26°c) will be started at a rate of 10 ml/kg for the first 30 minutes then reduced to 6 ml/kg till the end of the surgery.
- drug preparation:
An independent research assistant will be responsible for opening the envelopes and preparing the study drug with no further involvement in the study. The attending anesthetist and data collector will be blinded to the study group.
Group K (ketamine):
syringe (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.
syringe (2): saline syringe 10 ml saline in 10 ml syringe. (for double blinded technique). we will give 0.1ml/kg of the syringe.
Group KD (ketamine plus dexamethasone):
Syringes (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.
Syringe (2): dexamethasone syringe, 10 mg dexamethasone will be diluted with 10 ml saline in 10 ml syringe, concentration will be 1mg/ml. the dose will be 0.1 mg/kg, so we will give 0.1ml/kg of the syringe.
The drugs will be given to the patient by direct intravenous injection through the cannula and flushing with normal saline after administration of the drugs.
Recording of vital signs (arterial blood pressure, heart rate, oxygen saturation axillary temperature) then shifting the patient to the sitting position with a nurse in front of her for administration of subarachnoid block In the sitting posture, a 25G Quincke's spinal needle is used to puncture the L3-L4 interspace under sterile conditions and via the midline route.
After the CSF free flow, 12-15 mg hyperbaric bupivacaine will be givenIntrathecal (according to the patient's height) and the patient will be placed in a supine posture with 15 degrees tilt to left side with a wedge under right iliac bone. Patients will be given 3 liters of oxygen per minute through the nasal cannula.
After spinal anesthesia , arterial blood pressure, heart rate and oxygen saturation will all be recorded immediately after shifting the patient to supine position.
Hypotension is defined as a drop in mean arterial blood pressure (more than 20% below baseline) following spinal injection, and it is treated by increasing intravenous fluid administration and administering 2.5-5 milligrams increments of ephedrine I.V. (every 3-5 minutes) until the hypotension is resolved.
After the sensory block at the level of T4-T6 is confirmed by the lack of sensitivity to cold, surgery will begin. The heart rate, oxygen saturation,are continuously monitored and the blood pressure readings will be taken every 10 minutes till the end of the surgery.
During surgery, a shivering score will be recorded at 15 min intervals and axillary temperature will be recorded after 30 minutes then at the end of the surgery.
Rescue dose of pethidine (25 mg) could be given intravenously if the participant developed grade 3 or grade 4 shivering
- Apgar score of the baby will be recorded as a secondary outcome.
- The level of sedation of the mother using The University of Michigan Sedation Scale (UMSS) will be recorded.
Post operative monitoring:
The participants will be monitored post-operatively for 60 minutes regarding their hemodynamics and shivering score.
Any complications in the Intra operative and post-operative period will be recorded.
- Measurement tools
- Demographic data as age, sex, BMI, medications, drug allergy and any other comorbidity.
- Heart rate, SpO2, and non-invasive arterial blood pressure will be monitored and recorded before spinal anesthesia and every 10 minutes after spinal anesthesia till the end of the procedure.
- Length of operation and the number of shivering episodes scored ≥2 will be recorded.
- Temperature: axillary temperature will be measured before, immediately and 30 minutes after induction of spinal anesthesia, and at the end of surgery.
- Hemodynamics, temperature, shivering episodes will be recorded for 60 minutes postoperatively.
- Bedside Shivering Assessment Scale shivering score will be recorded at 15 min intervals till the end of the procedure and for 60 minutes in post anesthesia care unit
- Grade 0 if there is no shivering
- Grade 1 if there is no muscle contraction but mild fasciculation of face or neck or peripheral vasoconstriction but no visible shivering
- Grade 2 if there is a visible muscular activity in only one muscle group
- Grade 3 if the muscular activity is in more than one muscle group but not generalized
- Grade 4 if gross muscular activity involving the entire body.
- The level of sedation of the mother will be recorded using The University of Michigan Sedation Scale (UMSS).
Table 1: The University of Michigan Sedation Scale (UMSS)(Liu et al., 2018) Value Patient state 0 • Awake and alert.
- • Minimally sedated: tired/ sleepy, appropriate response to verbal conversation, and/or sound.
- • Moderately sedated: somnolent/ sleeping, easily aroused with light tactile stimulation or a simple verbal command.
- • Deeply sedated: deep sleep, roused only with significant physical stimulation.
- • Unarousable.
- .Table 2: Apgar score (Simon et al., 2017) Score 0 points 1 point 2 points Appearance (Skin color) Cyanotic / pale all over Peripheral cyanosis only. Pink Pulse (Heart rate) 0 <100 100-140 Grimace (Reflex irritability) No response to stimulation Grimace or weak cry when stimulated Cry when stimulated Activity (Tone) Floppy Some flexions Well flexed and resisting extension Respiration Apneic Slow, irregular Strong cry
VI. Study outcomes:
- Primary outcome:
- the incidence of shivering attacks intraoperative. ( using Bedside Shivering Assessment Scale)
- Secondary outcomes:
- Apgar score at 1 and 5 minutes, Apgar is a quick test performed on a baby at 1 and 5 minutes after birth. The 1-minute score determines how well the baby tolerated the birthing process. The 5-minute score tells the health care provider how well the baby is doing outside the mother's womb. It also helps measure how well the baby responds if resuscitation is needed right after birth.
- Intraoperative hemodynamics assessment Immediately after injection of the medications and every 10 minutes till the end of the procedure including: heart rate, arterial blood pressure and number of hypotensive episodes
- Sedation of the mother immediately after injection of drug and after 30 minutes using The University of Michigan Sedation Scale (UMSS)
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ketamine group | Active comparator | Drug: Ketamine HydrochlorideGroup K (ketamine): syringe (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe. syringe (2): saline syringe 10 ml saline in 10 ml syringe. (for double blinded technique). we will give 0.1ml/kg of the syringe. |
| ketamine dexamethasone group | Active comparator | Drug: Ketamine HydrochlorideGroup KD (ketamine plus dexamethasone): Syringes (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe. Syringe (2): dexamethasone syringe, 10 mg dexamethasone will be diluted with 10 ml saline in 10 ml syringe, concentration will be 1mg/ml. the dose will be 0.1 mg/kg, so we will give 0.1ml/kg of the syringe. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (13 listed)
- 1. Inclusion criteria
- 2. Exclusion criteria
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ketamine HydrochlorideAlso: dexamethasoneintravenous injection | Drug | ketamine dexamethasone group, ketamine group |
Primary outcome
number of shivering episodes
Time frame: the whole procedure and for 60 minutes postoperative
● the number of shivering episodes scored ≥3 will be recorded.
3 secondary outcomes
sedation score of the mother
Time frame: 120 minutes
APGAR score of the baby
Time frame: 5 minutes
hemodynamics
Time frame: 120 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2025.
Related trials for Intraoperative Shivering
Not yet recruitingPhase 4
Effect of Preoperative Intranasal Dexmedetomidine on Incidence of Intraoperative Shivering in Patients Undergoing Cesarean Section Under Spinal Anesthesia
Shivering, Hypothermia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ketamine Hydrochloride in people with Intraoperative Shivering and Ketamine With Shivering, run by Kasr El Aini Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
number of shivering episodes (time frame: the whole procedure and for 60 minutes postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2025.